Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progress in the management of gynecologic cancer: consensus summary statement.

× No keyword cloud information.

13 in total

1. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.

Authors: Dina Mury; Linn Woelber; Sabine Jung; Christine Eulenburg; Matthias Choschzick; Isabell Witzel; Joerg Schwarz; Fritz Jaenicke; Sven Mahner
Journal: J Cancer Res Clin Oncol Date: 2011-02-23 Impact factor: 4.553

Review 2. Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.

Authors: Bin Ai; Zhixin Bie; Shuai Zhang; Ailing Li
Journal: Am J Cancer Res Date: 2016-08-01 Impact factor: 6.166

3. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.

Authors: Xiaolong Wei; David Dombkowski; Katia Meirelles; Rafael Pieretti-Vanmarcke; Paul P Szotek; Henry L Chang; Frederic I Preffer; Peter R Mueller; Jose Teixeira; David T MacLaughlin; Patricia K Donahoe
Journal: Proc Natl Acad Sci U S A Date: 2010-10-15 Impact factor: 11.205

4. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

Authors: José María del Campo; Cristiana Sessa; Carolyn N Krasner; Jan B Vermorken; Nicoletta Colombo; Stan Kaye; Martin Gore; Patrik Zintl; Javier Gómez; Trilok Parekh; Youn Choi Park; Scott McMeekin
Journal: Med Oncol Date: 2013-02-09 Impact factor: 3.064

5. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.

Authors: Xianglin L Du; Rohan C Parikh; David R Lairson; Sharon H Giordano; Putao Cen
Journal: Med Oncol Date: 2013-01-10 Impact factor: 3.064

6. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential.

Authors: G Yin; A B Alvero; V Craveiro; J C Holmberg; H-H Fu; M K Montagna; Y Yang; I Chefetz-Menaker; S Nuti; M Rossi; D-A Silasi; T Rutherford; G Mor
Journal: Oncogene Date: 2012-02-20 Impact factor: 9.867

7. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.

Authors: Nathalie Rochet; Meinhard Kieser; Florian Sterzing; Sonja Krause; Katja Lindel; Wolfgang Harms; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus
Journal: BMC Cancer Date: 2011-01-28 Impact factor: 4.430

8. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.

Authors: P Oliva; A Decio; V Castiglioni; A Bassi; E Pesenti; M Cesca; E Scanziani; D Belotti; R Giavazzi
Journal: Br J Cancer Date: 2012-06-19 Impact factor: 7.640

9. Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer.

Authors: Arash Rafii; Eberhard Stoeckle; Mehdi Jean-Laurent; Gwenael Ferron; Philippe Morice; Gilles Houvenaeghel; Fabrice Lecuru; Eric Leblanc; Denis Querleu
Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240

Review 10. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer.

Authors: Levi Waldron; Benjamin Haibe-Kains; Aedín C Culhane; Markus Riester; Jie Ding; Xin Victoria Wang; Mahnaz Ahmadifar; Svitlana Tyekucheva; Christoph Bernau; Thomas Risch; Benjamin Frederick Ganzfried; Curtis Huttenhower; Michael Birrer; Giovanni Parmigiani
Journal: J Natl Cancer Inst Date: 2014-04-03 Impact factor: 11.816